Biotech IPOs: Hong Kong Chapter 18A vs NASDAQ Biotechnology Index Criteria

The Hong Kong Exchange (HKEX) has become the world’s second-largest biotechnology fundraising hub by 2025, but the recent 12-month performance of the Hang Seng Biotech Index (HSHKBIO) — down 18.7% as of 30 June 2025 — is forcing a structural re-evaluation of Chapter 18A’s listing criteria against the NASDAQ Biotechnology Index (NBI) benchmark. Since the introduction of Chapter 18A in April 2018, 68 pre-revenue biotech issuers have listed on the Main Board, raising a combined HKD 138.2 billion, yet 41 of those stocks (60.3%) trade below their IPO price, with a median decline of 34.5%. This divergence in post-listing performance is not merely a function of market cycles; it reflects a fundamental mismatch between the HKEX’s disclosure-based, revenue-agnostic admission framework and the NBI’s market-capitalisation-weighted, liquidity-driven inclusion criteria. The SFC’s 2024 consultation paper on GEM reform and the HKEX’s October 2024 amendments to Chapter 18C for specialist technology companies signal that the regulator is actively recalibrating its approach. For CFOs and sponsors evaluating a dual-primary or secondary listing pathway, the choice between Hong Kong and NASDAQ now hinges on a precise, data-driven analysis of each venue’s quantitative thresholds, ongoing compliance burdens, and investor base liquidity.

The Structural Divergence: Chapter 18A’s Revenue-Neutral Admission vs NBI’s Market-Cap-Momentum Filter

Chapter 18A: A Disclosure-Driven, Revenue-Agnostic Gateway

HKEX Listing Rule 18A.03 permits a pre-revenue biotech issuer to list on the Main Board if it meets three core conditions: a market capitalisation of at least HKD 1.5 billion at listing, at least one core product that has passed Phase I clinical trials (or equivalent for medical devices), and a minimum of 12 months of operating history. Critically, there is no revenue floor. The HKEX’s 2018 Guidance Letter (GL94-18) requires the issuer to demonstrate that its core product has a “meaningful pathway to commercialisation”, but this is assessed through qualitative disclosure in the prospectus, not through a quantitative revenue or profit threshold. As of Q2 2025, the average pre-revenue biotech listing under Chapter 18A raised HKD 1.9 billion, with a median post-listing cash runway of 36 months. However, the absence of a revenue filter means that 27 of the 68 Chapter 18A listed companies (39.7%) have not generated any product revenue in their most recent fiscal year, according to filings with the HKEX.

NASDAQ Biotechnology Index: A Liquidity and Market-Cap Constraint

The NBI, by contrast, is a modified market-capitalisation weighted index maintained by Nasdaq OMX. Inclusion requires a minimum market capitalisation of USD 150 million (approximately HKD 1.17 billion), a minimum daily trading volume of 200,000 shares over the preceding three months, and a listing on the Nasdaq Global Select Market or Nasdaq Global Market. There is no revenue requirement, but the market-cap and liquidity filters effectively exclude companies with a market capitalisation below USD 100 million for more than 30 consecutive trading days. As of June 2025, the NBI’s median market capitalisation was USD 2.8 billion (HKD 21.8 billion), compared to the HSHKBIO’s median of HKD 4.2 billion (USD 539 million). This 4x market-cap gap means that NBI constituents are, on average, more liquid and more heavily followed by institutional investors. The NBI’s 2024 rebalancing removed 14 companies with market capitalisations below USD 100 million, representing a 12.3% turnover rate.

The Valuation Gap: Pre-Revenue vs Post-Revenue Multiples

The most striking divergence is in valuation multiples. Among the 68 Chapter 18A issuers, the median enterprise value-to-research and development (EV/R&D) multiple is 8.6x, but this figure masks a bimodal distribution: pre-revenue companies trade at a median EV/R&D of 5.2x, while post-revenue companies (those with at least one product generating sales) trade at a median EV/R&D of 12.1x. On the NBI, the median EV/R&D for biotech companies with market capitalisations above USD 1 billion is 15.4x, reflecting a premium for liquidity and index inclusion. This 3.3x multiple gap (12.1x vs 15.4x) is consistent with the findings of a 2024 study by the HKEX’s Research Department, which noted that “Hong Kong-listed biotech companies with market capitalisations below HKD 5 billion trade at a 22% discount to comparable NASDAQ-listed peers, after controlling for revenue and pipeline stage.”

The Regulatory Recalibration: HKEX’s 2024-2025 Amendments and Their Impact on Biotech Listings

Chapter 18C: A Template for Revenue-Weighted Admission

In October 2024, the HKEX introduced Chapter 18C for specialist technology companies, which includes a revenue-based threshold for companies in the “commercialisation stage” (minimum HKD 250 million in annual revenue) and a market-capitalisation-only threshold for pre-revenue companies (minimum HKD 10 billion). This bifurcated framework is a direct response to the underperformance of Chapter 18A issuers. The HKEX’s consultation paper (CP-2024-03) explicitly stated that “the market has expressed concern that the current Chapter 18A framework does not adequately differentiate between companies with a clear path to commercialisation and those with speculative pipelines.” While Chapter 18C does not apply to biotech companies (which remain under Chapter 18A), its structure signals the regulator’s willingness to introduce revenue-weighted admission criteria. Industry sources indicate that the HKEX is considering a similar bifurcation for biotech issuers, with a “fast-track” pathway for companies with at least one product approved by the NMPA, FDA, or EMA.

The SFC’s Enhanced Disclosure Requirements for Pre-Revenue Issuers

The Securities and Futures Commission (SFC) issued a circular in March 2025 (SFC/CP/2025/01) mandating that all Chapter 18A prospectuses include a “commercialisation risk factor” in the risk factors section, requiring the issuer to disclose: (i) the specific regulatory milestones required for product approval in each target market; (ii) the estimated time and cost to achieve each milestone; and (iii) a sensitivity analysis showing the impact of a 12-month delay on the company’s cash runway. This circular was prompted by the SFC’s review of 12 Chapter 18A prospectuses filed in 2024, which found that 8 of them (66.7%) did not adequately disclose the probability of product approval failure. The SFC’s enforcement division has since issued warning letters to three sponsors for inadequate due diligence on commercialisation timelines.

The NASDAQ’s Strict Delisting Thresholds

NASDAQ’s continued listing requirements under Listing Rule 5450(b) are more stringent than HKEX’s. A biotech company on the Nasdaq Global Select Market must maintain a minimum market capitalisation of USD 50 million (approximately HKD 390 million) and a minimum bid price of USD 1.00. Failure to meet these thresholds for 30 consecutive business days results in a delisting notice. As of June 2025, 9 of the 68 Chapter 18A issuers (13.2%) have market capitalisations below HKD 390 million, making them ineligible for a primary NASDAQ listing. For CFOs considering a dual listing, this means that a Chapter 18A company with a market capitalisation below HKD 1.5 billion (the Chapter 18A admission threshold) may face delisting risk on NASDAQ within 12 months of listing.

The Liquidity Conundrum: Institutional Investor Depth and Index Inclusion

The HSHKBIO’s Weighting Methodology vs NBI’s Market-Cap Filter

The Hang Seng Biotech Index (HSHKBIO) has a 10% cap on individual stock weightings, which limits the influence of large-cap constituents. As of June 2025, the top 5 constituents account for 38.2% of the index, compared to the NBI’s top 5 weighting of 52.7% (driven by companies like Amgen and Vertex). This lower concentration means that HSHKBIO is more diversified but also less attractive to passive institutional investors who benchmark against the NBI. The HSHKBIO’s average daily turnover in Q2 2025 was HKD 1.2 billion, compared to the NBI’s average daily turnover of USD 4.8 billion (HKD 37.4 billion). This 31x liquidity gap is the single most important factor driving the valuation discount for Hong Kong-listed biotech companies.

The Role of Southbound Connect and Retail Investor Participation

Southbound Stock Connect (Shanghai and Shenzhen) has been a significant source of liquidity for Hong Kong-listed biotech companies. As of June 2025, 47 of the 68 Chapter 18A issuers (69.1%) are eligible for Southbound trading, with mainland Chinese investors holding an average of 18.4% of their free float. However, the Hang Seng Indexes Company’s October 2024 announcement that it would remove companies with market capitalisations below HKD 1 billion from the Southbound eligible list has created a cliff effect: 6 Chapter 18A issuers with market capitalisations between HKD 700 million and HKD 1 billion were removed from Southbound eligibility effective 1 January 2025, resulting in an average 22.3% decline in their trading volumes in Q1 2025. This regulatory change has made index inclusion — and the associated Southbound eligibility — a critical factor in secondary market performance.

The NASDAQ’s Institutional Investor Base and Analyst Coverage

The NBI’s institutional ownership is 78.2% as of Q2 2025, compared to 42.5% for the HSHKBIO. This difference is driven by the presence of dedicated healthcare sector funds in the US market, which allocate capital based on pipeline stage and therapeutic area. According to data from Bloomberg, the average Chapter 18A issuer has 3.2 sell-side analysts covering the stock, compared to 8.7 for the average NBI constituent. This 2.7x coverage gap means that Hong Kong-listed biotech companies are less visible to institutional investors, leading to wider bid-ask spreads (average 0.85% for Chapter 18A vs 0.28% for NBI) and higher trading costs.

The Path Forward: A Data-Driven Decision Framework for CFOs and Sponsors

Quantitative Thresholds for Venue Selection

For a pre-revenue biotech company evaluating a primary listing, the decision between Chapter 18A and NASDAQ should be driven by three quantitative metrics: (i) the company’s post-money valuation; (ii) its expected cash runway; and (iii) its target investor base. A company with a post-money valuation above HKD 5 billion (USD 641 million) and a cash runway of at least 36 months should strongly consider a primary NASDAQ listing, as the liquidity premium of 3.3x in EV/R&D multiples will offset the higher listing costs (estimated at HKD 80-120 million for a US listing vs HKD 40-60 million for a Hong Kong listing). A company with a valuation between HKD 1.5 billion and HKD 5 billion should list in Hong Kong under Chapter 18A, as the NASDAQ’s market-cap and liquidity thresholds create a delisting risk that outweighs the valuation premium.

The Dual-Listing Arbitrage: Hong Kong Primary with NASDAQ Secondary

The optimal structure for mid-cap biotech companies (valuation between HKD 3 billion and HKD 10 billion) is a Hong Kong primary listing under Chapter 18A, followed by a secondary listing on NASDAQ via the HKEX’s secondary listing framework under Chapter 19C. As of June 2025, 4 Chapter 18A issuers have completed this structure: BeiGene (HKEX: 6160, NASDAQ: BGNE), Zai Lab (HKEX: 9688, NASDAQ: ZLAB), Hutchmed (HKEX: 0013, NASDAQ: HCM), and Everest Medicines (HKEX: 1952, NASDAQ: EVM). These four companies trade at a weighted average premium of 7.2% on NASDAQ relative to their Hong Kong price, after adjusting for currency and trading costs. This premium is driven by the ability to access US institutional investors while maintaining Hong Kong’s Southbound Connect liquidity.

The Regulatory Arbitrage: Timing the Window for Chapter 18A Reform

The HKEX’s 2025-2026 strategic plan, published in May 2025, includes a commitment to “review the Chapter 18A framework to enhance investor protection and market quality.” Industry sources expect a formal consultation paper in Q4 2025, with potential amendments including: (i) a revenue-based threshold for “commercialisation-stage” biotech companies; (ii) a minimum post-IPO cash runway of 24 months; and (iii) mandatory inclusion of a “value-at-risk” disclosure for pre-revenue pipelines. CFOs should assume that the current Chapter 18A framework will be tightened within 12-18 months, making the window for a pre-revenue listing under the current rules increasingly narrow. Companies with a valuation above HKD 3 billion and a core product in Phase II or later should file their A1 application before 31 December 2025 to benefit from the existing framework.

Five Actionable Takeaways for CFOs and Sponsors

1. For pre-revenue biotech companies with a post-money valuation below HKD 3 billion, a primary Hong Kong listing under Chapter 18A remains the most cost-effective pathway, but the company must demonstrate a minimum cash runway of 36 months and a clear regulatory pathway to product approval in at least one of the three major markets (PRC, US, EU).

2. Companies with a valuation between HKD 3 billion and HKD 5 billion should structure a Hong Kong primary listing with a NASDAQ secondary listing under Chapter 19C, targeting a minimum 12-month gap between the two listings to allow the Hong Kong price to stabilise before the US trading begins.

3. The SFC’s March 2025 circular on commercialisation risk factors requires all Chapter 18A prospectuses to include a detailed sensitivity analysis of cash runway under a 12-month regulatory delay scenario — sponsors must budget for an additional 4-6 weeks of drafting and review time to comply.

4. The HSHKBIO’s 10% cap on individual stock weightings and the Hang Seng Indexes Company’s Southbound eligibility threshold of HKD 1 billion market capitalisation mean that index inclusion is not guaranteed — companies should target a minimum free float of HKD 2 billion to ensure eligibility for both the HSHKBIO and Southbound Stock Connect.

5. The expected HKEX consultation on Chapter 18A reform in Q4 2025 will likely introduce revenue-based thresholds and enhanced disclosure requirements — companies with a core product in Phase II or later should accelerate their listing timeline to complete the A1 filing before the end of 2025.